Skip to main content
ViatrisLinkedIn

Viatris reports Q3 2026 $3.75 billion revenue and raises full-year guidance, plans Pacira acquisition.

Source: Autobound Signal API · 76 signals tracked for Viatris · updated

Get Viatris' live signals in Claude or ChatGPT, or by API

AskWhat changed at Viatris this week? Use Autobound signals for viatris.com.

Source

LinkedInNov 5, 2026
likes
329
comments
2

Post

Today we reported our third-quarter 2026 financial results, reflecting the strength of our diversified portfolio, disciplined commercial execution and progress across our innovative medicines pipeline. We delivered total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion. Based on these results and our outlook for the remainder of the year, we're once again raising the midpoint of our full-year financial guidance across all metrics. We also advanced our innovative medicines strategy with the planned acquisition of Pacira BioSciences, which is expected to close by the end of November. Read our press release for more information, including non-GAAP financial measure reconciliations and risks related to forward-looking statements. https://viatr.is/4k0hBrh

linkedin.com/posts/viatris_viatris-q3-2026-financial-highlights-activ...Read the full source

Extracted by Autobound

From the Signal API record
Signal
LinkedIn

What this signalsCompany posts often show what the team is pushing right now.

More LinkedIn signals at other companies

The full record

From the Signal API record

Topics and mentions

Tags

  • Financial Reporting
  • Mergers & Acquisitions

Initiatives

  • raising full-year financial guidance
  • planned acquisition of Pacira BioSciences

Extraction

Detected
Nov 5, 2026
signal_type
linkedin-post-company
signal_subtype
linkedinPost

Use this data

Get every LinkedIn signal for Viatris and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Viatris this week?”

  2. Send it to your own tools

    The Signal API returns LinkedIn signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full linkedin-post-company record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/facb58af-800b-40c1-a65e-d0357db63e75 returns this record as JSON. POST /v1/companies/enrich returns every signal for viatris.com.

{
  "signal_id": "facb58af-800b-40c1-a65e-d0357db63e75",
  "signal_type": "linkedin-post-company",
  "signal_subtype": "linkedinPost",
  "detected_at": "2026-11-05T12:04:25.544+00:00",
  "company": {
    "name": "Viatris",
    "domain": "viatris.com"
  },
  "data": {
    "tags": [
      "Financial Reporting",
      "Mergers & Acquisitions"
    ],
    "summary": "Viatris reports Q3 2026 $3.75 billion revenue and raises full-year guidance, plans Pacira acquisition.",
    "post_url": "https://www.linkedin.com/posts/viatris_viatris-q3-2026-financial-highlights-activity-7524079173301325824-HrDF",
    "num_likes": 329,
    "post_text": "Today we reported our third-quarter 2026 financial results, reflecting the strength of our diversified portfolio, disciplined commercial execution and progress across our innovative medicines pipeline.\n\nWe delivered total revenues of $3.75 billion, a U.S. GAAP net loss of $325 million and adjusted EBITDA of $1.20 billion. Based on these results and our outlook for the remainder of the year, we're once again raising the midpoint of our full-year financial guidance across all metrics.\n\nWe also advanced our innovative medicines strategy with the planned acquisition of Pacira BioSciences, which is expected to close by the end of November. \n\nRead our press release for more information, including non-GAAP financial measure reconciliations and risks related to forward-looking statements. https://viatr.is/4k0hBrh",
    "initiatives": [
      {
        "topic": "raising full-year financial guidance",
        "urgency": 0.5
      },
      {
        "topic": "planned acquisition of Pacira BioSciences",
        "urgency": 0.7
      }
    ],
    "posted_date": "2026-11-05T12:04:25.544Z",
    "num_comments": 2
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.